Acute Myocardial Infarction Market Summary
The Acute Myocardial Infarction market was valued at around USD 1,630 million in 2025 and is projected to reach nearly USD 5,392 million by 2034, growing at a notable CAGR of 14.2% during the study period from 2020 to 2034.
Among the 7MM countries, the United States is expected to account for the largest Acute Myocardial Infarction market size, accounting for approximately 75% of the overall market in 2023. The total incident cases of Acute Myocardial Infarction in the 7MM were approximately 1,468,400 in 2023, with the highest incident cases recorded in the United States.
The increasing use of cardiac biomarkers for diagnosing Acute Myocardial Infarction during the past two decades – along with the changing cutoff levels for laboratory tests used to define myocardial injury – represents one of the most apparent complicating factors in many studies of AMI trends. The use of biomarkers has likely improved the ascertainment of myocardial infarction over time, with the dual effects of potentially masking actual reductions in disease incidence due to primary prevention efforts, and leading to false improvements in myocardial infarction-related case fatality attributable to the inclusion of smaller infarctions that previously would have been clinically unrecognized.
Among the total Acute Myocardial Infarction incident cases, NSTEMI type were estimated to be more prevalent than STEMI type, with NSTEMI accounting for approximately 607,300 cases in the United States alone in 2023.
The Acute Myocardial Infarction market research landscape is being reshaped by a new generation of platelet antagonists. Zalunfiban and selatogrel represent exciting novel subcutaneously administered agents that may be delivered easily at first medical contact in patients with STEMI, potentially transforming the pre-hospital treatment paradigm.
Key companies including Idorsia Pharmaceuticals and Viatris (Selatogrel), Recardio (Dutogliptin), Amgen (Olpasiran), Faraday Pharmaceuticals (FDY-5301), Novo Nordisk (Ziltivekimab), Bristol Myers Squibb and Johnson & Johnson Innovative Medicine (Milvexian), CeleCor Therapeutics (Zalunfiban), Kancera (KAND567), CellProthera and BioCardia (ProtheraCytes), and others are evaluating their lead candidates across different stages of clinical development, and will significantly impact the market during the forecast period (2024–2034).
Acute Myocardial Infarction Overview
Acute Myocardial Infarction (AMI) is myocardial necrosis resulting from acute obstruction of a coronary artery. Symptoms include chest discomfort with or without dyspnea, nausea, and/or diaphoresis. AMI is one of the leading causes of death in the developed world and can be divided into two primary categories: non-ST-segment elevation MI (NSTEMI) and ST-segment elevation MI (STEMI). Unstable angina is clinically similar to NSTEMI; however, cardiac markers are not elevated in such cases.
Treatment modalities include antiplatelet drugs, anticoagulants, nitrates, beta-blockers, statins, and reperfusion therapy. For STEMI, emergency reperfusion is achieved via fibrinolytic drugs, percutaneous intervention, or, occasionally, coronary artery bypass graft (CABG) surgery. For NSTEMI, reperfusion is typically via percutaneous intervention or CABG surgery.
Acute Myocardial Infarction Diagnosis
The initial evaluation of a patient with suspected AMI includes a focused clinical history, physical examination, electrocardiography (ECG), cardiac markers, and a chest radiograph. An ECG is especially useful for distinguishing between NSTEMI and STEMI. Serum biomarkers include cardiac-specific troponins T and I, MB isoforms of creatine (CK-MB), creatine kinase (CK), and myoglobin. Myocardial injury may also be diagnosed through wall motion abnormalities on echocardiography, though echocardiography cannot definitively distinguish between an acute STEMI and an old myocardial scar. Other notable differential diagnoses include acute pericarditis, pulmonary embolism, acute aortic dissection, costochondritis, and gastroesophageal reflux disease.
Acute Myocardial Infarction Treatment
The goals of initial treatment include relief of pain, immediate identification of ST changes via 12-lead ECG, initiation of reperfusion where indicated, and assessment of hemodynamic abnormalities. Pain relief is best achieved with oxygen, nitroglycerin, and morphine sulfate. Patients with ST-segment elevation or a new left bundle branch block (LBBB) with symptoms for 12 hours or less are candidates for reperfusion therapy. Further treatment is segmented into pathways depending on whether the patient presents with STEMI or NSTEMI.
Acute Myocardial Infarction Epidemiology
The Acute Myocardial Infarction market insight is strongly informed by robust epidemiological data across the 7MM. The AMI epidemiology section covers historical and forecasted data segmented by total incident cases, type-specific incidence, and gender-specific incidence across the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan from 2020 to 2034.
- The total incident cases of Acute Myocardial Infarction in the United States were estimated at approximately 822,800 in 2023, with cases expected to increase by 2034.
- In Japan, there were approximately 45,700 cases of STEMI and 34,500 cases of NSTEMI in 2023.
- In EU4 and the UK, incident cases were approximately 930,900 in males and 537,500 in females in 2023.
Acute Myocardial Infarction Epidemiology Segmentation:
- Total Incident Cases of Acute Myocardial Infarction
- Type-specific Incident Cases of Acute Myocardial Infarction (STEMI vs. NSTEMI)
- Gender-specific Incident Cases of Acute Myocardial Infarction
Marketed Acute Myocardial Infarction Therapies
LODOCO (colchicine) – AGEPHA Pharma
Colchicine, an anti-inflammatory alkaloid with a history spanning ancient Egypt, has assumed a critical role in contemporary cardiovascular inflammation management. As the first FDA-approved targeted anti-inflammatory cardiovascular therapy, LODOCO holds a unique role in the management of atherosclerotic cardiovascular disease. In June 2023, the US FDA approved LODOCO as the first anti-inflammatory atheroprotective cardiovascular treatment demonstrated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or multiple cardiovascular risk factors. Patients with residual inflammatory risk now have, for the first time, an FDA-approved treatment specifically designed to target inflammatory pathways contributing to major cardiac events.
TNKase (tenecteplase) – Genentech
TNKase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology. Tenecteplase is a variant of native tPA with 14-fold greater fibrin specificity than alteplase, a longer half-life, slower plasma clearance, and 80-fold greater resistance to plasminogen activator inhibitor type 1. Its half-life of approximately 18 minutes allows for single-bolus administration. In June 2000, the US FDA approved TNKase to reduce mortality associated with AMI.
Emerging Acute Myocardial Infarction Therapies
The Acute Myocardial Infarction market trends are rapidly evolving, with several high-potential pipeline candidates poised to transform standards of care:
Dutogliptin – Recardio
Dutogliptin (REC-01) is a potent and selective DPP4 inhibitor administered via subcutaneous injection. The combination of G-CSF with dutogliptin has significantly enhanced survival and reduced infarct size in preclinical models. Once AMI diagnosis is confirmed and percutaneous intervention is completed, the patient receives daily subcutaneous injections of dutogliptin for 2 weeks in co-administration with G-CSF for 5 days.
- In March 2024, Recardio completed its first partnering agreements, closing with regional partners outside its key territories (US and Europe) to support a global pivotal Phase III study for dutogliptin.
Selatogrel – Idorsia Pharmaceuticals and Viatris
Selatogrel is a potent, highly selective, fast-acting, and reversible P2Y12 receptor antagonist self-administered subcutaneously via an autoinjector upon the onset of AMI-suggestive symptoms. In 2020, the FDA granted Fast Track designation for selatogrel for treating suspected AMI in adult patients with a history of AMI.
- In February 2024, Idorsia announced a significant global R&D collaboration with Viatris for the development and commercialization of selatogrel and cenerimod, with an upfront payment of USD 350 million, potential development and regulatory milestones, and tiered royalties on annual net sales.
Leading Acute Myocardial Infarction Companies
The leading Acute Myocardial Infarction companies developing therapies include Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, and others. These organizations are collectively advancing a robust pipeline that is expected to substantially reshape treatment paradigms and commercial dynamics during the forecast period.
Conclusion
The Acute Myocardial Infarction market is at a defining inflection point, shaped by rising disease burden, a rapidly maturing pipeline, and landmark regulatory approvals. The convergence of improved diagnostics, greater clinician and patient awareness, and incremental global healthcare spending is expected to drive sustained market expansion through 2034. The emergence of subcutaneously self-administered agents, first-in-class anti-inflammatory therapies, and novel platelet antagonists signals a fundamental transformation in how AMI is treated – from the emergency room to the patient’s home. With a healthy competitive landscape and increasing investment from both established pharmaceutical giants and innovative biotech firms, stakeholders across the value chain stand to benefit from this growing therapeutic market.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
